New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
05:49 EDTTEVASynthon says glatiramer shows equivalence to Teva's Copaxone
Synthon announced that the companyís glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple sclerosis. The Phase III Glatiramer Acetate clinical trial to assess equivalence with Teva's (TEVA) Copaxone is to-date the only Phase III study conducted with a generic version of Copaxone and has demonstrated an equivalent efficacy and safety profile for Synthonís glatiramer acetate compared to Copaxone, Synthon said. Synthon has already submitted an Abbreviated New Drug Application for glatiramer acetate for injection in pre-filled syringes to the FDA in November 2011.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:11 EDTTEVATeva reported great Q3 results, says BMO Capital
Subscribe for More Information
09:06 EDTTEVATeva says assessing M&A opportunities of all sizes
08:49 EDTTEVATeva says may pursue generic businesses in emerging markets
Says not ruling out "transformational" transactions. Says open to specialty assets in U.S., Europe.
08:40 EDTTEVATeva says $5.00-$5.10 FY14 EPS guidance is for exclusive Copaxone scenario
Subscribe for More Information
07:06 EDTTEVATeva board authorizes increase in share repurchase program to $3B
The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.
07:05 EDTTEVATeva raises FY14 EPS view to $5.00-$5.10 from $4.90-$5.10
Subscribe for More Information
07:05 EDTTEVATeva reports Q3 EPS $1.32, consensus $1.23
Subscribe for More Information
October 27, 2014
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use